Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
|Videos|January 9, 2014
Recent Advancements in Non-Small Cell Lung Cancer
Author(s)Bilal Piperdi, MD
Bilal Piperdi, MD, discusses the recent advancements in non-small cell lung cancer treatment and what the future might bring.
Advertisement
Bilal Piperdi, MD, Associate Professor of Clinical Medicine, Department of Medicine (Oncology), Albert Einstein College of Medicine, discusses the recent advancements in non-small cell lung cancer treatment and what the future might bring.
Clinical Pearls:
- There have been improvements in molecular testing
- Physicians have learned that it is not just the histology that determines the biology of these patients; it is different mutations that define the biology of this disease
- More advances in molecular testing would allow for clinicians to test for multiple mutations at a time, including some of the uncommon mutations
- The challenge in the future will be learning how the different mutations interact and what targets can better treat the cancer
Advertisement
Related to this article
Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies, yet gaps persist, and research funding uncertainty threatens future gains.
For Hispanic Heritage Month, Narjust Florez, MD, discusses lung cancer risk, biomarker testing, and trial access in Hispanic and Latinx patients.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
Upfront Surgery Vs Total Neoadjuvant Therapy in Rectal Cancer
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5